LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) will report fourth quarter and full-year 2025 financial results after market close on March 9, 2026 and will host a conference call and webcast at 4:30 p.m. Eastern the same day.
Dial-in numbers, conference ID LIFEMD, and a live/archived webcast link will be available for investors.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, LFMD was weak while momentum scanning showed only MNDR with notable action, moving -6.57%. Broader peers (HCAT, SLP, SOPH, CCLD) showed mixed single-day moves, suggesting stock-specific positioning rather than a coordinated sector move around this earnings date.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Credit facility | Positive | +7.9% | Announced up to $50M senior secured revolving credit facility with Citizens Bank. |
| Jan 05 | Partnership expansion | Positive | +12.0% | Expanded Novo Nordisk collaboration to offer newly approved Wegovy pill via telehealth. |
| Dec 26 | Preferred dividend | Neutral | -12.5% | Declared cash dividend on 8.875% Series A Cumulative Perpetual Preferred Stock. |
| Nov 24 | Growth recognition | Positive | +3.1% | Recognized on Deloitte Technology Fast 500 and TIME’s America’s Growth Leaders list. |
| Nov 17 | Q3 2025 earnings | Positive | +2.2% | Reported Q3 2025 revenue and EBITDA growth with improved balance sheet metrics. |
Recent fundamentally positive announcements (credit facility, partnership, Q3 earnings, growth recognitions) mostly saw positive price reactions, with one notable divergence on a preferred dividend announcement.
Over the past several months, LifeMD reported multiple constructive developments. On Nov 17, 2025, Q3 2025 results showed revenue growth and improved profitability, followed by recognitions for growth on Nov 24, 2025. In early January 2026, the company expanded its Novo Nordisk collaboration and closed a revolving credit facility of up to $50 million, both met with positive stock reactions. A preferred dividend announcement on Dec 26, 2025 coincided with a decline. Today’s Q4 2025 earnings date fits into this cadence of regular financial updates.
Market Pulse Summary
This announcement sets the timetable for LifeMD’s Q4 and full-year 2025 results on March 9, 2026, with a conference call at 4:30 p.m. Eastern. In recent quarters, the company reported revenue growth, improved profitability, and secured new credit capacity, while also expanding strategic partnerships. Investors monitoring this event may focus on whether financial trends from Q3 2025 continue and how management frames growth, balance sheet flexibility, and any follow-up on prior accounting adjustments.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
| Date: | Monday, March 9th |
| Time: | 4:30 p.m. Eastern time |
| Toll-Free Dial-In: | 800-343-5172 |
| International Dial-In: | 203-518-9856 |
| Conference ID: | LIFEMD |
| Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
FAQ
When will LifeMD (LFMD) release Q4 and full-year 2025 results?
How can investors join the LifeMD (LFMD) earnings call on March 9, 2026?
What time is the LifeMD (LFMD) conference call for Q4 2025 results?
Will LifeMD (LFMD) provide a webcast of the March 9, 2026 earnings call?
What information will LifeMD (LFMD) report for the period ending December 31, 2025?
